-+ 0.00%
-+ 0.00%
-+ 0.00%

NervGen Pharma management commentary: Higher R&D and administrative costs widen Q3 2026 net loss

PUBT·11/17/2026 19:39:09
Listen to the news
NervGen Pharma management commentary: Higher R&D and administrative costs widen Q3 2026 net loss
  • NervGen Pharma management commentary reported a third-quarter net loss of CAD 6.41 million versus CAD 4.72 million for the period ended September 30, 2026.
  • Management attributed the wider loss to higher research and development spending, alongside increased general and administrative costs, partially offset by warrant-derivative gains.
  • Research and development expenses reached CAD 7.9 million, primarily reflecting costs to initiate the Phase 3 NVG-291 trial in chronic tetraplegia.
  • Nine-month net income reached CAD 2.47 million, primarily driven by noncash gains on warrant derivatives related to US-dollar-denominated warrants.
  • Cash and cash equivalents totaled CAD 80.12 million at September 30, supported by the May public offering.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NervGen Pharma Corp. published the original content used to generate this news brief on November 17, 2026, and is solely responsible for the information contained therein.